PharmTech News

Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.

Articles

Teva said it plans to appeal a district court decision that invalidated several of the company’s Copaxone patents.

District Court Rules Against Teva in Copaxone Patent Lawsuit

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Alexandre Juillerat, PhD, innovation senior scientist at Cellectis, discusses novel construct UCART123, an investigational agent that is on deck to be the first gene-edited T-cell product in the United States.

Honing in on the Tumor Microenvironment

Despite the threat of competition, both from biosimilars to Humira and new therapies that work through other mechanisms of action, AbbVie says Humira is still number one.

AbbVie: Despite Competition, Humira Still the Number-One Prescribed Biologic

ADMA will acquire BPC’s plasma-based fractionation and purification plant in Boca Raton, FL and plans to resolve issues at the facility noted in an FDA warning letter.

ADMA Biologics to Acquire Plasma-Based Biologics Facility from Biotest

The company will gain the rights to a mutein that is believed to help maintain immune system homeostasis.

Celgene Adds New Fusion Protein to Portfolio with Delinia Acquisition

The companies will split Actellion’s drug discovery and early-stage clinical development assets into a new Swiss biopharmaceutical company.

J&J to Acquire Actelion for $30 billion

After a positive Phase II trial, the company said its C. difficile vaccine candidate will advance to Phase III trials during the first half of 2017.

Pfizer Releases Positive Top Line Results from C. Difficile Trial

Merck will pay a one-time fee of $625 million and additional royalties to BMS and Ono Pharmaceutical to settle the patent infringement case related to Keytruda.

Merck Settles Litigation with Bristol-Myers Squibb on Use of Antibody Targeting PD-1

The company will begin trials with its CBD chewing gum, CanChew Plus, for the treatment of irritable bowel syndrome.

Axim Biotechnologies Begins Clinical Trials with CBD Chewing Gum

Luke Miels will replace Abbas Mussain as president of GSK’s Global Pharmaceutical division later this year.

Bio/Pharma News